

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The Dal-GenE trial	Range Agreed	6	8	Date Agreed	31/12/2018	23	12/11/2018	23	Recruitment Finished	Study wide Recruitment Target Met
15/SC/0295	177196	An open label, single arm, multicenter study to assess the clinical effectiveness and safety of Lynparza (olaparib) capsules maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients who are in complete or partial response following platinum based chemotherapy (ORZORA)	Range Agreed	2	4	Date Agreed	30/09/2018	5	06/07/2018	5	Withdrawn By Host	Oncology Research Service Moved to Another Hospital
17/LO/0438	217257	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT	Number Agreed	10	10	Date Agreed	30/06/2019	0	15/11/2018	0	Withdrawn By Host	Confirmation of C&C issued but sponsor did not issue green light and study was abandoned at site due to unforeseen resources issue at site